Aclaris Therapeutics
ACRS
104 hedge funds and large institutions have $737M invested in Aclaris Therapeutics in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 54 increasing their positions, 24 reducing their positions, and 13 closing their positions.
1,097% more call options, than puts
Call options by funds: $4.24M | Put options by funds: $354K
125% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 24
10.48% more ownership
Funds ownership: 95.81% → 106.29% (+10%)
6% more capital invested
Capital invested by funds: $694M → $737M (+$42.2M)
1% less funds holding
Funds holding: 105 → 104 (-1)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$32.2M |
| 2 |
BlackRock
New York
|
+$13.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.96M |
| 4 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$7.05M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FHAM
Folger Hill Asset Management
New York
|
-$8.04M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.56M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$4.22M |
| 4 |
PC
PointState Capital
New York
|
-$4.08M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.36M |
ACRS Hedge Fund Activity: Q3 2017 in Review
104 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2017, worth a combined $737M — up 6.1% from $694M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ACRS and 12 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 54 added.
The largest buyer was Deerfield Management, adding an estimated $32.2M. The largest seller was Folger Hill Asset Management, exiting entirely with an estimated $8.04M sold.
- 104 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2017, down from 105 in Q2 2017.
- Funds reported $737M of Aclaris Therapeutics stock for Q3 2017, up 6.1% quarter-over-quarter.
- 12 funds opened new Aclaris Therapeutics positions in Q3 2017 and 13 closed out, a net change of -1 holder.
- The largest Aclaris Therapeutics buyer in Q3 2017 was Deerfield Management, an estimated $32.2M added.
- The largest Aclaris Therapeutics seller in Q3 2017 was Folger Hill Asset Management, an estimated $8.04M sold.
Based on aggregated 13F filings for Q3 2017.